Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Escalation of Xeloda or 5-FU with Taxotere and Radiotherapy for Advanced NSCLC
NCT00256841Phase 2Withdrawn
- Start
- Sep 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in non-small cell lung cancer (NSCLC). Planned start Sep 2005; status: withdrawn.
02
Drugs
capecitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00256841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256841.